Argonautic Ventures
Argonautic Ventures is a venture capital firm that invests in companies developing AI-enabled, data-centric products and workflows, including in financial technology, construction technology, and computational biotechnology. It partners with founders from pre-seed through later stages, providing capital and hands-on support to help build and scale businesses.
Facts
- HQ
- Seattle, WA, US
- Founded
- 2016
- Employees
- 11
- Invests in
- We are a venture capital firm with AI at our core. Our mission is to build data-centric companies both horizontally at the infrastructure level and vertically in industries ripe for creative disruption—focusing on financial technology, construction technology, and computational biotechnology.
- Stages
- Pre-seed, Seed, Series A, Series B and later
Is this your organization? Claim it
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Conxai Raises $5.8M Series A Led by BayBG Venture Capital and Capricorn Partners to Expand AI Construction Platform
Conxai, a Munich-based construction tech company led by CEO Sharique Husain, raised $5.8M in a Series A round co-led by BayBG Venture Capital and Capricorn Partners to expand operations and grow its no-code agentic AI platform used by AEC and industrial clients globally.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
People
See all 15-
Brent Xu Venture Partner
-
Carter Davidson Operating Partner
-
Chase Cho Strategic Partner